Table 3. Determinants of asthma control status over 12 weeks of treatment.
| Well-controlled n=46 | Partly controlled n=68 | Uncontrolled n=14 | P* | P† | |
|---|---|---|---|---|---|
| MON-400BUD:800BUD | 24:22 | 37:31 | 4:10 | 0.204 | 0.307 |
| Gender (M:F) | 22:24 | 31:37 | 6:8 | 0.935 | 0.706 |
| BMI (kg/m2) | 24.7±2.8 | 24.6±3.3 | 26.1±2.6 | 0.231 | 0.018 |
| Changes from baseline | |||||
| FEV1% | 2.3±10.7 | 0.4±9.6 | -4.2±9.2 | 0.101 | 0.015 |
| ACT score | 2.0±3.0 | 0.2±4.2 | -2.8±4.7 | <0.001 | 0.013 |
| AQoL | 2.3±11.4 | -0.9±22.0 | -10.8±25.8 | 0.091 | 0.910 |
| 6-min walk distance, m | 14.9±61.2 | 5.5±56.9 | -10.5±127.0 | 0.530 | 0.032 |
| PFS (mobility) | 1.0±13.0 | -3.4±18.6 | -17.9±22.6 | 0.002 | 0.018 |
| PFS (self-care) | 1.7±8.1 | 0.9±12.2 | -11.9±20.9 | 0.001 | 0.033 |
| PFS (total) | 1.3±7.3 | -1.3±12.0 | -15.1±20.4 | <0.001 | - |
| GDS | -0.4±1.6 | 0.3±1.6 | 0.4±1.8 | 0.074 | 0.201 |
*ANOVA and Pearson's χ2; †Multivariate ordinal regression analysis with reference to the uncontrolled group.
MON-400BUD, combination therapy consisting of montelukast and low-dose inhaled budesonide; 800BUD, monotherapy consisting of a medium dose of inhaled budesonide; BMI, body mass index; FEV1%, percentage of expected volume exhaled at the end of the first second of forced expiration; ACT, asthma control test; AQoL, asthma-specific quality of life questionnaire; PFS, physical functioning scale; GDS, geriatric depression score.